NimBio

If you're attending DxPx Conference Europe 2025, let's connect! We'd love to discuss potential collaborations and share insights on improving Inflammatory Bowel Disease (IBD) patient care. We look forward to connecting with industry leaders, investors, and potential partners to discuss advancements in proactive care for Inflammatory Bowel Disease (IBD) patients. Our solution offers effortless and remote care, enabling early detection of flares and personalized treatment plans. A special thank you to EIT Health for the invitation and continued support. Maria Sanchis, PhD Christian Kunze #NimBio #DxPxEurope2025 #DigitalHealth #IBD #PatientCare #Innovation #Networking

🌟 Exciting News from NimBio! 🌟 We are thrilled to announce that NimBio is among the thirty most promising life science and healthtech start-ups in Europe! We’ve been selected as a semifinalist in the 9th Edition of the prestigious EIT Health Catapult competition! 🎉 This program brings together Europe's leading innovators, providing an exceptional platform to showcase our transformative vision to industry experts and top investors. This achievement follows our success in the EIT Health Open Innovation IBD Challenge, EIT Health Belgium-Netherlands. At NimBio, our mission is to revolutionize proactive care for patients with Inflammatory Bowel Diseases (IBD). Our flagship innovation, the Inflammometer™, is a groundbreaking non-invasive technology designed to passively collect real-time data for the early detection of flares in chronic inflammatory diseases. By doing so, we aim to reduce hospitalizations and complications through timely treatment optimization. We are excited to advance our innovation with the support of the EIT Health community. Stay connected and cheer us on as we strive for a spot in the finals! 🚀 #NimBio #EITHealthCatapult #HealthTech #Innovation #LifeSciences #StartupJourney #HealthcareRevolution #InflammatoryBowelDiseases eHealthVentures Venturing Tech

We are thrilled to share that our portfolio company NimBio won the EIT Health Open Innovation Programme for inflammatory bowel diseases (IBD)! NimBio is at the forefront of healthcare innovation, developing cutting-edge technology to monitor inflammatory biomarkers. This breakthrough allows for the effortless and non-invasive early detection of flares, revolutionizing the management of Inflammatory Bowel Disease (IBD). Winning this competition marks a significant milestone, opening doors to collaborate with EIT Health, KU Leuven, and Takeda. These collaboration efforts will make effortless, non-invasive early flare detection a reality for millions of IBD patients, improving their quality of life and healthcare outcomes. This achievement is a testament to our NimBio’s dedication and the impact of their technology. Here is to wishing them luck on their great journey!  #NimBio #EITHealth #IBD #HealthInnovation #Winner #Gratitude

🎉 We’re excited to announce that NimBio is the proud winner of the EIT Health Open Innovation Challenge for Inflammatory Bowel Disease (IBD)! 🏆 We look forward to collaborating with EIT Health, Severine Vermeire Elke Piters KU Leuven, and Geert Van Gassen Takeda to make effortless, non-invasive early flare detection a reality for millions of IBD patients. Special thanks to the EIT program leaders Hayley Every, Christian Kunze, Maria Sanchis, PhD, and Magda Krakowiak for orchestrating such a vital platform to improve collaboration and innovation in critical health issues. Special thanks to those supporting us on this journey, eHealthVentures Talor Sax Joseph Rosenblum Yossi lovton Ophir Shahaf, Venturing Tech Roel Schoondermark, Amnon Bar-Lev, Nir Kalkstein, and Ron Levkovich. Your encouragement and guidance have been invaluable. Here’s to continuing the journey of innovation and significantly impacting the lives of those affected by IBD! #Innovation #Healthcare #EITHealth #Takeda #KULeuven #IBD #MedicalInnovation #Teamwork #ThankYou EIT announcement: https://lnkd.in/d97pAudH

NimBio is thrilled to announce its selection as a finalist in the EIT Health Open Innovation Programme for inflammatory bowel diseases (IBD), in partnership with Takeda and KU Leuven We are proud to share NimBio has been selected into the first cohort for the Open Innovation IBD Challenge to advance our promising technology for early detection of IBD flares and optimizing disease management. Here at NimBio, we are dedicated to improving the quality of life for individuals affected by IBD. Our cutting-edge technology utilizes inflammatory biomarkers tracked effortlessly through non-invasive and continuous digital measurements, enabling proactive and remote disease management. Join us on this journey. Let's make an impact together! Discover more about the programme: https://lnkd.in/diX3i5HQ hashtag #IBD #EITHealth eHealthVentures Venturing Tech

https://lnkd.in/dPY-q5qN